focus -WSS

focus

author：knowledge 2025-09-28 15:21:06 - browse：6472

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

focus

WSS

Parkinson’s finding may lead to tests and, someday, treatments

Independent physicians launch a new lobbying group

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Investigation reveals sickle cell patients pressured into sterilizations

The surgeon had a dilemma only a Nazi medical text could resolve

H5N1 bird flu outbreak: Second human case reported, in Michigan

focus

focus

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Digital health: a case of mistaken identity

United colonoscopy coverage change 'may cost lives,' doctors say

Eyeing GLP

Moonlake's readout produced a cash windfall. Risks remain

Listen: More tumult at BIO & coercive care for sickle cell patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Francis Collins on trust in science and how Covid communications failed

In Memoriam: Notable people who died in 2023

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

Citing H5N1 threat, CDC urges peak flu monitoring this summer

AI generated plenty of interest at JPM but not a lot of trust

As a primary care physician, here's how I hope to partner with AI

Biogen joins immunology wave with $1.15 billion acquisition of HI

NIH director takes cautious approach to Biden drug pricing priority

My yearlong odyssey to get my son’s ADHD medication covered

focus

hotspot

focus

focus